Bleomycin Sulfate

For research use only. Not for use in humans.

製品コードS1214 別名:NSC125066

Bleomycin Sulfate化学構造

分子量(MW):1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

サイズ 価格(税別) 在庫  
JPY 30200 あり
JPY 113200 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(36)

質量管理及び製品安全説明書

Antineoplastic and Immunosuppressive Antibiotics阻害剤の選択性比較

生物活性

製品説明 Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
体外試験

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 M4H2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nndFDjiJNzMECwJO69dQ>? NXXTR|RlOjRiaNMg MkTubY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NF\P[nczPjB6OEexNS=>
POLK WT MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfYeHJKSzVyPUGxMlfjiIoEsfMAjVEvP8LizszN NIixPWczPjB|MUSwNC=>
POLK KO NUm3NGt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTRwMERihKnDueLCiUGuPVLDqM7:TR?= MUmyOlA{OTRyMB?=
POLK CD MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjtN5ZKSzVyPUWuOVnjiIoEsfMAjVEvODEEoN88US=> NUmyfXBbOjZyM{G0NFA>
RLE/Abca3 MXTGeY5kfGmxbjDBd5NigQ>? MmnBNE41yqEQvF2= M1TpWlE1PMLiaB?= NG\ob|VqdmS3Y3XzJIEhdW:{cHjvcI9ocWOjbDDjbIFv\2ViZoLvcUBmeGm2aHXsbYFtNWyra3WgcY9zeGixbH;nfUB1dyCjIIfp[IUtKHOycnXh[E1wfXRibX;ydIhwdG:pedMg M2jhbVI2PzZyNUO4
PMCs MnTnSpVv[3Srb36gRZN{[Xl? NX3ad|FDOC5z4pETNuKh|rypL33s MmfPNlTDqGh? Mk[4Z4F2e2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKHC{b4TlbY4hdGW4ZXygc4Yh[2:ubHHn[Y4uUcLi NUS1T3FYOjV3OUW2OFI>
PMCs NWKx[2dDTnWwY4Tpc44hSXO|YYm= NYnUcnNEOC5{wrFOwIcwdWx? NGfrcI0zPOLCk{eyxsBp NXz0R4tTcW6mdXPld{BqdmO{ZXHz[ZMhcW5idnnt[Y51cW5iYX7kJO6yNVOPQTDwdo91\Wmw MnHVNlU2QTV4NEK=
PMCs NF3ndIJHfW6ldHnvckBCe3OjeR?= NUjvUYV3OC5{wrFOwIcwdWx? MliyO|IhcA>? M2jDXYlv\HWlZYOg[IVkemWjc3XzJIlvKGO7dH;r[ZJifGmwLUigZY5lKEVvY3HkbIVzcW5icILveIVqdg>? M1zyR|I2PTl3NkSy
PMCs NF\4boxHfW6ldHnvckBCe3OjeR?= MnToNE4zyqEQvHevcYw> MX6xNk8zPC92ODDo M1\0ZYlv[3KnYYPld{Bk\WyuIH3p[5JifGmxbh?= M2\zN|I2PTl3NkSy
IMR-32 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor3O{426ojUMUKwJOK2\y:vbB?= MWKxNwKJmjR6IHi= MXjJR|UxRTZyINM1[{9udCCjdDD0bIUh\W6mIH;mJFI1KGi{czDv[kBqdmO3YnH0bY9v NGK1WWszPTV|NkO0OS=>
HT1080 NWG1cmloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVWxJO69VQ>? MnPDNlQhcMLi MWrs[YFleyC2bzDhJGczN01iZHXsZZk> NWnycoVmOjV3MUi5OlE>
HT1080 MV3GeY5kfGmxbjDBd5NigQ>? NFnkXnAyKM7:TR?= MYCyOEBpyqB? MYLpcoR2[2W|IHGgdI91\W62IHfsc4JidCCGTlGg[IFu[WenIILld5BwdnOn MkXiNlU2OTh7NkG=
HDFn NHjVeFREgXSxdH;4bYNqfHliQYPzZZk> M{jDOlczKGh? NGXXXFhKSzVyPUmuN|EmyqB? MWmyOVI4Pjd7Mh?=
THP-1 NHnDendEgXSxdH;4bYNqfHliQYPzZZk> NGTjZZU4OiCq Ml;DTWM2OD12Lke3KS=> MVWyOVI4Pjd7Mh?=
HT-29 MkPVR5l1d3SxeHnjbZR6KEG|c3H5 NV;NfoZuPzJiaB?= MlriTWM2OD1zMT60PUU> M1fJVVI2Ojd4N{my
HCT116  NVPZTJFMS3m2b4TvfIlkcXS7IFHzd4F6 MljyO|IhcA>? NIq5RodKSzVyPUGxMlM1LQ>? M2rxdFI2Ojd4N{my
A431 NX3aWZNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zR[|UxNTJyMDDJWS=> M3y5fVQ56oDLaB?= NV\0bnRPcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NUe1S5kyOjVzMEGyPVk>
T24 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnscpN4PTBvMkCwJGlW MYK0PQKBkWh? NXnx[lFVcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MoP1NlUyODF{OUm=
AY-27  NITNO|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;sfFN5PTBvMkCwJGlW NF3KTJg1QOLCiXi= NEX0WIVqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MlrxNlUyODF{OUm=
A549 M2qwPWZ2dmO2aX;uJGF{e2G7 NFvpZpAyKML3Zz;tUOKh M1nkZlAuPDhiaB?= MYnpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=> M3fVdVI1QTZ|NkO1
MLE12 NVXLS|Z6TnWwY4Tpc44hSXO|YYm= M2jscVEhyrWpL33MxsA> MVWwMVQ5KGh? MXrpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=> NVvuOFF[OjR7NkO2N|U>
Jurkat NFr2e25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXTNlDjiIoQvH2= MYSyOQKBkWkEoB?= MYrhdpJme3S|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=> NUXmSld2OjR7MU[4PVM>
HeLa  NXPwZ5hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfB[FNKSzVyPUGwMlLDqM7:TR?= M3;3UlI1PzN{M{m3
C18-4 NWLVNI5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrJU3AxNTFyMDFOwG0> MWjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NXLnVYhVOjR3N{G5PFI>
BMG-1  NIjofYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnGxOFAwQDEEoN88[{9u MoDEN:KhcA>? MkfibY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MWWyN|kxPjd{Nh?=
A459 NGPne3VCeG:ydH;zbZMhSXO|YYm= Mk\jNVAhdVV? MnnwOFghcA>? M4TFT4lv\HWlZYOgZZBweHSxc3nz MlzpNlM6ODJ5Nk[=
MOCK MVLBdI9xfG:|aYOgRZN{[Xl? NXHpXGs4OTBibWW= M{m2NVQ5KGh? NEPyOYFqdmS3Y3XzJIFxd3C2b4Ppdy=> MnHuNlM6ODJ5Nk[=
MMP1 MlnSRZBweHSxc3nzJGF{e2G7 Ml74NVAhdVV? NYTyZ2V5PDhiaB?= Ml3vbY5lfWOnczDhdI9xfG:|aYO= M1zLZlI{QTB{N{[2
A549 NGTkbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTye2pXOjByIN88US=> NWTrfG5pOjRiaNMg M1T3boRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MlPuNlM5ODV5OUO=
HCT-116 MVfBdI9xfG:|aYOgRZN{[Xl? M4\wN|MwPy53L{G1JO69\y:vbB?= MVW0PEBp MVPy[YR2[2W|IITo[UBt\X[nbDDv[kBDVEhiYYSgbIlocCClb37j[Y51emG2aX;u NXK1WmJnOjN5MEi2Olg>
HeLa NXPWTYRsSXCxcITvd4l{KEG|c3H5 NFnGN4U{NzdwNT:xOUDPxGdxbXy= MWC0PEBp NHryWZhz\WS3Y3XzJJRp\SCuZY\lcEBw\iCETFigZZQhcGmpaDDjc45k\W62cnH0bY9v M1\ORVI{PzB6Nk[4
HCT116 M3foeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED5OZQxNTFyMDFOwIcwdWx? NIG3NHM1QCCq NEjscGNqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M1PoWlI{PTF6MkCx
NCM460 NWfVUW1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nvPFAuOTByIN88[{9udA>? MYq0PEBp MWnpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NFjQOJYzOzVzOEKwNS=>
NT2  NF;uZ3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTVTlczPCCqwrC= MVXMSFUxRTRyMPMAjeK2\y:vbB?= MojSNlM{QDZ2MkC=
NT2  MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXu0PEBp NEjRTnBNTDVyPUGwNEDDvWdxbXy= M3ewS|I{Ozh4NEKw
NT2  M2KxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTJO|IhcA>? MVfMSFUxRTJy4pEJxtVoN22u MX[yN|M5PjR{MB?=
NT2  MVjBdI9xfG:|aYOgRZN{[Xl? MmXzOFAx6oDLwsXnM41t MYOyOEBpyqB? MXjpcoR2[2W|IIPp[45q\mmlYX70JIlv[3KnYYPld{BqdiClYYPwZZNmNTNuODy5JIFkfGm4aYT5xsA> MW[yN|M5PjR{MB?=
NTera-2 M1vYNmZ2dmO2aX;uJGF{e2G7 MU[xNlAh|rypL33s NF\4fVk4OiCq M2DlT5Nq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz NVHldGd2OjJ6MkWzOVU>
NCCIT MnHkSpVv[3Srb36gRZN{[Xl? MYqxNlAh|rypL33s MlfVO|IhcA>? NUfKV4xWe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgPE1qe2:ycn;zeIFv\SCuZY\lcJM> NVHu[HliOjJ6MkWzOVU>
NTera-2 MX\GeY5kfGmxbjDBd5NigQ>? NUjURlh1OTJyIN88[{9udA>? NUX3bJNOPzJiaB?= NYrSN|Z4e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ NV\IXGVbOjJ6MkWzOVU>
NCCIT NEnufnpHfW6ldHnvckBCe3OjeR?= NUSyRoFsOTJyIN88[{9udA>? NUHKOHFSPzJiaB?= MnPZd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiVFLBVnMhdGW4ZXzz M1fXT|IzQDJ3M{W1
NCCIT M4Dse2Z2dmO2aX;uJGF{e2G7 MmK2NVIxKM7:Zz;tcC=> NU\WfZdFPzJiaB?= NVn4RYFKe2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgS3NJKGyndnXsdy=> MYqyNlgzPTN3NR?=
NTera-2 NVeyV|B2TnWwY4Tpc44hSXO|YYm= M1f5OFEzOCEQvHevcYw> NUPmPYt3PzJiaB?= M3;qcJNq\26rZnnjZY51dHliaX7jdoVie2W|IGDyc5RmcW5iY3HyZo9vgWxibHX2[Yx{ M{jldVIzQDJ3M{W1
NCCIT MojESpVv[3Srb36gRZN{[Xl? MVixNlAh|rypL33s NIP0cpQ4OiCq NFfUXpp{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDQdo91\WmwIHPhdoJwdnmuIHzleoVtew>? M33Gc|IzQDJ3M{W1
NTera-2 NGjGWFdHfW6ldHnvckBCe3OjeR?= M{LqSlEzOCEQvHevcYw> M4XRWlczKGh? MUjzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCOUF:gcIV3\Wy| NWTPUGppOjJ6MkWzOVU>
NCCIT MkTJSpVv[3Srb36gRZN{[Xl? NHPzPHkyOjBizsznM41t M13qbFczKGh? NG\Tcnh{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDMVG8hdGW4ZXzz MV[yNlgzPTN3NR?=
MDA-MB-468 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrZ[|Ex6oDVMkCwxsDPxGdxbVy= MX[yOEBp NHzMZ5VqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MmDuNlI5OTlzOU[=
231-H2N Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG4[VAx6oDVMkCwxsDPxGdxbVy= M3jkVlI1KGh? M2jaO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MlTnNlI5OTlzOU[=
A549  NEm2OI1HfW6ldHnvckBCe3OjeR?= M{n6SlIxOC92MECg{txO M13nUpJme3WudIOgbY4h[SCmb4PlMZJme3CxboPpeoUhcW6lcnXhd4UhcW5iUl;T MX6yNlc4OzZ7Nx?=
A549  M3jkc2Z2dmO2aX;uJGF{e2G7 MoPMNE01ODBizszN NIrpVW0zNTR6IHi= NFTJO2Nk[XW|ZYOgcY9z\SCvdFTORUB1cGGwIH7EUmEh\GGvYXfl MUKyNlc4OzZ7Nx?=
A549  MWHGeY5kfGmxbjDBd5NigQ>? M{HINVExOCEQvF5CpC=> MkXjNQKBmzR6IHi= NUX1[pc{[2G3c3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v NH\oUZczOjd5M{[5Oy=>
A549  NEG1V3lHfW6ldHnvckBCe3OjeR?= M2\3WlExOCEQvF5CpC=> NGTYPWYx6oDVNEigbC=> NIjBd29k[XW|ZYOgVGtFOSClbHXheoFo\Q>? MV:yNlc4OzZ7Nx?=
A549  NEDMT5ZHfW6ldHnvckBCe3OjeR?= NUnNPGZ7OTByIN88UeKh NIDRZZQx6oDVNEigbC=> MnXvZ4F2e2W|IH3peI9kcG:wZILpZYwhdG:lYXzpfoF1cW:wIH;mJGJigA>? MXmyNlc4OzZ7Nx?=
A549  M1LtdGZ2dmO2aX;uJGF{e2G7 MnnVNVAxKM7:TdMg NV70bVhyOOLCk{S4JIg> NWjtWYtW\GWlcnXhd4V{KE2PUDDhcoQhSVSSIHzleoVtew>? MlfONlI4PzN4OUe=
MCF-7/Her-18  NGrue2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P1SlAvPDJvMUewNEDPxGdxbVy= M2fDflI1KGh? NFHub2xqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 Mn;tNlI3OjF2MES=
MCF-7 MVXQSHQwWEOLIGTy[YF1dWWwdB?= NEm5WWoxNjJ3IN88[{9udC5? NEDSOWUyNTRiaB?= MV3zbI94eyC|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0 MnLRNlI2QTF{OES=
MDA-MB-231 M4HUd3BFXC:SQ1mgWJJm[XSvZX70 Mnj1NE4zPSEQvHevcYwv MXOxMVQhcA>? NVzzcph{e2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? NVPl[mx3OjJ3OUGyPFQ>
MDA-MB-235  NVGxUZpqWESWL2DDTUBVemWjdH3lcpQ> MlPmNE4zPSEQvHevcYwv NIC2XmoyNTRiaB?= NWDXSmZKe2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? NGDmNGYzOjV7MUK4OC=>
MCF-7 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O2ZlAuOiEQvHevcYwv NIfWWFczPC92ODDo MYfFR|UxRTFwMjFOwIcwdUx? MXeyNlU6OTJ6NB?=
NCCIT  M1;GUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXVUGIzOOLCk{G0NOKh|rypL33s NXm2bZZUPzJiaB?= MnXiUGQ2OD1zMkFCpO69\y:vbNMg NIfEfYYzOjV4MkG2NC=>
NCCIT  M3TlVmZ2dmO2aX;uJGF{e2G7 NGft[XY4OiCq NX\CTJVNe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5xsA> NWPOdG8{OjJ3NkKxOlA>
NCCIT  MoTISpVv[3Srb36gRZN{[Xl? MnjyO|IhcA>? MWLzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNThiYXP0bZZqfHoEoB?= NUXUXWdrOjJ3NkKxOlA>
NCCIT  MUnGeY5kfGmxbjDBd5NigQ>? Ml;5O|IhcA>? NIfQRWN{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUmgZYN1cX[rdIpCpC=> NEHT[4QzOjV4MkG2NC=>
NCCIT  MVPGeY5kfGmxbjDBd5NigQ>? NV;qcoFRPzJiaB?= Mn3Vd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiQlHYJIxmfmWu MYCyNlU3OjF4MB?=
NCCIT  M2X3W2Z2dmO2aX;uJGF{e2G7 MV23NkBp NIrj[FR{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUhSmOuLUKgZ49vfGWwdB?= NH\Le4UzOjV4MkG2NC=>
NCCIT  NHuxUHJHfW6ldHnvckBCe3OjeR?= MVq3NkBp MVHzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgR5l1NWNibHX2[Yw> MljONlI2PjJzNkC=
HeLa M2juZmZ2dmO2aX;uJGF{e2G7 M2DJb|MxNzdyIN88[{9udA>? MoLRNlTDqGh? MlLEbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKheDV|78{MRXRONHB{MdMgZY5lyqCJQVTEOFU> MkXMNlI1QDd7M{e=
MCF-7  M2nmdmZ2dmO2aX;uJGF{e2G7 NGWxbYI{OC95MDFOwIcwdWx? MV:yOOKhcA>? NFnlVGNqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCyNURvwKxCXE1ucEKxxsBidmUEoFfBSGQ1PQ>? NIf4fm4zOjR6N{mzOy=>
HeLa MmD3R5l1d3SxeHnjbZR6KEG|c3H5 MXSzNE84OCEQvHevcYw> MoHaNlTDqGh? M3TPfolv\HWlZYOgbIlocGy7IIPp[45q\mmlYX70JIxmfmWuczDv[kBnemGpbXXueIVlKESQQTDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bR?= NYTDcWYxOjJ2OEe5N|c>
MCF-7  MVHDfZRwfG:6aXPpeJkhSXO|YYm= M2T4UlMxNzdyIN88[{9udA>? MYmyOOKhcA>? MlexbY5lfWOnczDobYdpdHlic3nncolncWOjboSgcIV3\Wy|IH;mJIZz[WevZX70[YQhTE6DIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOv NH7a[ZozOjR6N{mzOy=>
NT2 M3fIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjDVnVEOTByLU[wNOKh|rypL33s M{XhWlI1KGh? NVLVdmFpUUN3ME20NFAhyrWpL33s M4CycFIzPDZ7OUWy
NT2 MV3GeY5kfGmxbjDBd5NigQ>? M2Dwb|QxOMLizsznM41t MnnPNlQhcA>? NIfD[2Z{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUOsPEw6KGGldHn2bZR6yqB? NIiweVEzOjR4OUm1Ni=>
NT2 NFTo[mFHfW6ldHnvckBCe3OjeR?= NU\6[Ho3PDBywrFOwIcwdWx? MoSxNlQhcA>? Ml7Ed4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiQlHYJIxmfmWu NXHGNJJHOjJ2Nkm5OVI>
NT2 MVfGeY5kfGmxbjDBd5NigQ>? NFficY01ODEEoN88[{9udA>? MUGyOEBp MYfzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCEY3ytNkBt\X[nbB?= MmTONlI1Pjl7NUK=
CHO MXrGeY5kfGmxbjDBd5NigQ>? MUCyMlXDqM7:Zz;tcC=> MWqxPEBpNzZiZB?= NIDoZ4NqdmS3Y3XzxsBx\XK|aYP0[Y5k\SCxZjDjbJJwdW:|b33lJIRidWGpZR?= M{HMOlIzOjNyMUm1
Jurkat NU\mZYhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTVWnd5OC1zMEFCpO69\y:vbB?= M3GwSVI1KGh? MkT5ZZJz\XO2czD0bIUh[2WubDDjfYNt\SCjdDD0bIUhTzJicHjhd4U> MkjsNlIzOjN|M{K=
Jurkat NV7xU2c2TnWwY4Tpc44hSXO|YYm= M3HJW|MxyqEQvHevcYw> NInuNoczPCCq NUTiW2ZNcW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDjfYNtcW6|IFSzMEBCKGGwZDDCNS=> NXn0VmczOjJ{MkOzN|I>
Jurkat MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[zU2IxNTFyMNMg{txoN22u MVWyOEBp MmXFbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiYX6gTWM2OCC4YXz1[UBw\iBzMEFOwIcwdUx? M{XsWFIzOjJ|M{Oy
Jurkat MXnGeY5kfGmxbjDBd5NigQ>? MU[zNOKh|rypL33s Ml2yNlQhcA>? M3v6XIlv[3KnYYPld{B1cGViZX\m[YN1KG:oIID5Z45q\GmxbnWgc44heGixc4Doc5J6dGG2aX;uJIxmfmWuczDv[kBpcXO2b37lJGgzSS6[ MYGyNlIzOzN|Mh?=
U2OS EGFPnls MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLrNE0zyqEQvHevcYw> M2[xOVI1KGh? MY\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NXfNbIx7OjF6MUGwNFc>
U2OS KuEnls NWfWOlBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7kZlVjOC1{wrFOwIcwdWx? NYL3T3ljOjRiaB?= Ml3NbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M3vFVFIyQDFzMEC3
MCF-7 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi5UocxNTRyMDFOwG0> NFz2TIk4OiCq NXzVNm5VVEN3ME2xOVEvQMLizszN NXzsPYwyOjF5MEOyPVE>
MCF-7/Adr  NFXLd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW0SY0xNTRyMDFOwG0> Mme5O|IhcA>? NECxeG9NSzVyPUW4MlXDqM7:TdMg NHSwWYgzOTdyM{K5NS=>
WI-38 NWm3O2h1TnWwY4Tpc44hSXO|YYm= MX:wM|QxNzhy4pEJ{txoN22uwrC= M{P5V|MhcA>? M1T4PIlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> M1rD[lIyPTl7NkGy
hBMSC NUHXcZRkTnWwY4Tpc44hSXO|YYm= MlHCNE81OC96MPMAje69\y:vbNMg MnO1N{Bp M13VXIlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> M{fROFIyPTl7NkGy
NCI-H23 NHLJR41HfW6ldHnvckBCe3OjeR?= Mnn3NE81OC96MPMAje69\y:vbNMg M2jEblMhcA>? NFvFeVVqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh MX6yNVU6QTZzMh?=
A-549 NWX3e2xOTnWwY4Tpc44hSXO|YYm= MX2wM|QxNzhy4pEJ{txoN22uwrC= MVOzJIg> NYn6XnhTcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? M2HW[|IyPTl7NkGy
PBL  MYnGeY5kfGmxbjDBd5NigQ>? M13jR|AwPDBxOEFihKnPxGdxbX|CpC=> NF3ENms{KGh? MWTpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg MXiyNVU6QTZzMh?=
pol β −/− NFW5XphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nlW|AvOjVvMkCwxsDPxGdxbXy= MU[yOOKhcA>? Mlq0[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfpeIghcW6lcnXhd4lv\yClb37j[Y51emG2aX;ud:Kh MWiyNVI2OTl2NB?=
pol β +/+ MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q2TVAvOjVvMkCwxsDPxGdxbXy= MX6yOOKhcA>? M4HtWYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD3bZRpKGmwY4LlZZNqdmdiY3;uZ4VvfHKjdHnvcpPDqA>? NIfuT2MzOTJ3MUm0OC=>
pol β −/− MVnGeY5kfGmxbjDBd5NigQ>? M4f5dlAuOi53IN88[{9udA>? NHTDS4YzKGh? NF7FWpNk[XW|ZYOgSG5CKGSjbXHn[S=> NXHTenZxOjF{NUG5OFQ>
pol β +/+ MWHGeY5kfGmxbjDBd5NigQ>? M1z4ZlAuOi53IN88[{9udA>? MmfONkBp NUPxOWt3[2G3c3XzJGRPSSCmYX3h[4U> MWSyNVI2OTl2NB?=
pol β −/− MYjGeY5kfGmxbjDBd5NigQ>? NYT4VlNVOC13IN88[{9udA>? MYW0PEBp NViyZ3Jo[2G3c3XzJI1q[3KxboXjcIV2eyCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 NVHMemtsOjF{NUG5OFQ>
pol β +/+ M3j3fmZ2dmO2aX;uJGF{e2G7 M4fMOVAuPSEQvHevcYw> NWnDZ2N2PDhiaB?= MYXjZZV{\XNibXnjdo9vfWOuZYXzJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= NWfJTJJvOjF{NUG5OFQ>
TK6  NXLxPWgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDM[FUzPS1zNUCg{txoN22u MljaPVYhcA>? M3XtSolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M1zhbVIyODhzNEi3
TK6  sLUC+Apn1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LKNFI2NTF3MDFOwIcwdWx? M3fPXVk3KGh? MkfpbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M3roc|IyODhzNEi3
TK6 sAPE1+Apn1 MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvKfIgzPS1zNUCg{txoN22u Mm\CPVYhcA>? Mn\ad4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7 MnLCNlExQDF2OEe=
HCT116 NXP5TGo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrDd5QzPS1zNUCg{txoN22u NHqwcHo6PiCq MW\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MW[yNVA5OTR6Nx?=
HCT116 sLUC+Apn1 NETOPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LIT|I2NTF3MDFOwIcwdWx? MnG2PVYhcA>? MUnpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NE\oOGIzOTB6MUS4Oy=>
HCT116 sAPE1+Apn1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DWc|I2NTF3MDFOwIcwdWx? NUXUWmZzQTZiaB?= NWDBUYZwe2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 Mn7uNlExQDF2OEe=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
LRP6 / Wnt5AB / Dvl2 / β-catenin; 

PubMed: 27649046     


CRL-1490 cells were treated with the indicated concentrations of bleomycin for either 12 or 24 h, and then probed for canonical Wnt proteins LRP6, Wnt5AB, Dvl2, and β-catenin. 

phospho-eIF2α / eIF2α; 

PubMed: 23762310     


Western blotting analysis of phosphorylated, total eIF2α and β-actin in CT26 treated 24 h with the indicated drugs. BLM: Bleomycin

cytochrome c; 

PubMed: 20154224     


mitochondrial release of cytochrome c was detected by Western blot in cytosolic extract and analyzed by band densitometry. Data show the means of four independent experiments ± SE. *Statistical significance from control, P < 0.05. Representative Western blots are shown.

Bcl-xl; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-xL.

Bcl-2; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-2.

27649046 23762310 20154224
Immunofluorescence
LC3; 

PubMed: 23762310     


CT26 cells were cultured on glass slides and treated with indicated drugs for 24 h. The cells were then submitted to anti-LC3 (green) and DAPI (blue) labeling and observed under an epifluorescence microscope. BLM: Bleomycin

23762310
ELISA
HMGB1; 

PubMed: 23762310     


HMGB1 was titrated with ELISA method in supernatant of CT26 cells treated 24 h with indicated drugs. BLM: Bleomycin

23762310
体内試験 Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

お薦めの試験操作(参考用のみ)

細胞試験:

[4]

- 合併
  • 細胞株: ADIPO-P2 cells
  • 濃度: 2.5 μg/mL
  • 反応時間: 30 minutes
  • 実験の流れ:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (参考用のみ)
動物試験:

[7]

- 合併
  • 動物モデル: CD-1 mice
  • 投薬量: 5 mg/kg, 2 ml/kg
  • 投与方法: Administered via i.t.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (66.11 mM) warming
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
Saline
混合させたのち直ちに使用することを推奨します。
30 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 1512.62
化学式

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
in solvent
別名 NSC125066
Smiles CC(O)C(NC(=O)C(C)C(O)C(C)NC(=O)C(NC(=O)C1=C(C)C(=NC(=N1)C(CC(N)=O)NCC(N)C(N)=O)N)C(OC2OC(CO)C(O)C(O)C2OC3OC(CO)C(O)C(OC(N)=O)C3O)C4=C[NH]C=N4)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C.O[S]([O-])

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • 回答:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

Tags: Bleomycin Sulfateを買う | Bleomycin Sulfate ic50 | Bleomycin Sulfate供給者 | Bleomycin Sulfateを購入する | Bleomycin Sulfate費用 | Bleomycin Sulfate生産者 | オーダーBleomycin Sulfate | Bleomycin Sulfate化学構造 | Bleomycin Sulfate分子量 | Bleomycin Sulfate代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID